XRx-101

XORTX Japan patent decision covers XRx-101 for kidney injury

Image
XORTX Japan patent decision covers XRx-101 for kidney injury

CALGARY — November 13, 2026 -- The Japan Patent Office (JPO) has issued a Decision to Grant for XORTX Therapeutics' application covering six claims on xanthine oxidase inhibitor compositions, including oxypurinol, for acute kidney injury linked to viral infection. Once registered, it will be the Nasdaq-listed company's first Japanese patent for its xanthine oxidase inhibitor programs and is expected to run to March 15, 2041, exactly 21 years after its March 15, 2020 U.S. priority filing, by FairsOnline's calculation.

The patent is not yet in force. It issues only after XORTX pays the registration fee and the JPO registers it. The company did not say when it expects registration. The expiry date is subject to annuity fees and excludes any patent term extension that may become available.